logo
Brisk walks could cut risk of death for colon cancer patients by more than a third, study finds

Brisk walks could cut risk of death for colon cancer patients by more than a third, study finds

Yahoo4 days ago

A structured exercise routine can reduce the risk of death for people with colon cancer by more than a third, a study has found.
The results, unveiled at the American Society of Clinical Oncology (ASCO) conference on Sunday, could transform how colon cancer is treated around the world, the researchers said.
The scientists hope the findings will prompt healthcare providers to integrate exercise plans into routine cancer care.
The CO21 CHALLENGE trial, published in the New England Journal of Medicine, followed 889 people with colon cancer across six countries, including the UK.
It found that a structured exercise programme significantly reduced the likelihood of the disease returning and improved overall survival compared with standard advice.
After five years, 80 per cent of patients who followed a tailored exercise regime were cancer-free, compared with 74 per cent of those who were offered just health education materials.
This means the risk of dying, cancer coming back, or developing a new cancer was 28 per cent lower in the exercise group.
After eight years, survival rates were 90 per cent in the exercise group compared to 83 per cent in the health education group, representing a 37 per cent lower risk of death.
More than 31,000 people in the UK die from colon cancer every year, according to Cancer Research UK.
The study was part-funded by Cancer Research UK's Stand Up To Cancer campaign and carried out in collaboration with the Canadian Cancer Trials Group (CCTG).
The three-year programme saw patients supported by physical activity consultants, starting with weekly in-person sessions for the first six months and moving to monthly sessions either in person or online. Activities were tailored to the individual, from brisk walking to gym-based circuit training.
Among the patients to benefit from the trial was Margaret Tubridy, 69, from north Belfast.
Before her cancer diagnosis, she said she had never exercised. Now, five years on, she says she is lifting weights, pole walking and taking part in gym classes twice a week.
'It's been almost five years since my cancer diagnosis and if I meet anyone, I tell them I am doing great,' she said.
'Taking part in the trial helped me so much – I am stronger, fitter, and my anxiety is better. I never thought at 69 years of age I would be able to do all of this – I am chuffed to bits.'
Professor Vicky Coyle, UK lead researcher and clinical professor at Queen's University Belfast, said the study gives 'clear and encouraging' evidence that physical activity can reduce colon cancer mortality.
'We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate,' she said.
Cancer Research UK said the findings should act as a wake-up call for health services, adding it could 'transform clinical practice'.
However, Caroline Geraghty, senior specialist information nurse at the charity, said this can only happen 'if health services have the necessary funding and staff to make it a reality for patients'.
She added: 'It's important to remember that every cancer journey is different – starting new activities after treatment can feel overwhelming, and it may not be the right option for everyone. Take things at your own pace and speak to your doctor to discuss what is safe for you.'
The researchers said more work is needed to explore the biological mechanisms behind exercise's effect on cancer, but the evidence is already strong enough to prompt urgent action.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lack of doctors causing cancer delays
Lack of doctors causing cancer delays

Yahoo

timean hour ago

  • Yahoo

Lack of doctors causing cancer delays

A senior radiologist has said there are not enough doctors to keep up with the number of cancer patients needing scan results, diagnosis and treatment. Dr Tom Roques, vice president of clinical oncology at the Royal College of Radiologists, who also works at Norwich and Norfolk University Hospital, claimed the NHS was struggling to meet the government's 62-day diagnosis targets in cancer care. However, Steffan Aquarone, North Norfolk MP, believed another significant challenge was ensuring patients in rural areas could access treatment. A spokesman for the Department of Health and Social Care said: "We are determined to tackle delays, diagnose cancer earlier and treat it faster." Dr Roques described a shortage of both radiologists and doctors. He said: "People are waiting for scan results or waiting for diagnoses and we're also really short of cancer doctors. "There are delays further down the line in actually having that treatment because there aren't enough people to provide it." However, he says the problem was not just a Norfolk issue. "We are just not able to meet the government-set targets which themselves, are not that ambitious really. "If you don't have the staff and nurses and the physical space to treat them [patients] then people are not going to be able to have the treatment they deserve." Matt Sample, from Cancer Research UK, said the 62-day government target had been missed annually since 2015, with 74,000 people not beginning treatment within that target last year. He said: "For people affected by cancer, every single day waiting to get that diagnosis and begin treatment is a worrying and stressful time even when they are seen within targets. "When those targets are missed, those worries and stresses are just compounded - it can impact their treatment options and ultimately their outcomes. Liberal Democrat Aquarone agreed, saying "more people die than are necessary". He remains concerned about the ability of people in rural areas to get cancer care. "This is entirely about access to treatment," he said. Julie Keeling, nurse director for planned care at Norwich and Norfolk University Hospital, said: "Our latest validated figures show that as of March 2025, 51.8 % of patients receiving first treatment for cancer are treated by day 62, with 48.2 % of patients waiting over 62 days for first cancer treatment. It is encouraging that this is an improvement on previous data. "We know that we have more to do and are sorry that some patients have had to wait longer than expected to see us following a cancer referral." The Department of Health and Social Care said: "We are delivering 40,000 more appointments every week, investing £1.5bn in both new surgical hubs and AI scanners, rolling out cutting-edge radiotherapy machines to every region in the country and backing our radiologists and oncologists with above inflation pay rises for the second year in a row." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X. Cancer patient's treatment was delayed - coroner Hospital praised for breast cancer surgery wait time Hospital has second-longest waiting time for care NHS struggling to provide safe cancer care, say doctors Department of Health and Social Care Norwich and Norfolk University Hospital NHS Foundation Trust Cancer Research UK

Massive Bio Recognized in Two Key Categories on CB Insights' AI Drug Research & Development Market Map
Massive Bio Recognized in Two Key Categories on CB Insights' AI Drug Research & Development Market Map

Business Wire

time12 hours ago

  • Business Wire

Massive Bio Recognized in Two Key Categories on CB Insights' AI Drug Research & Development Market Map

CHICAGO--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights' latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio's innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions. "Being recognized in two critical categories by CB Insights is a testament to the power of AI in transforming oncology care." Share CB Insights' market map highlights companies at the forefront of leveraging AI to accelerate drug discovery and development. Massive Bio's inclusion in both the 'Clinical Trial Matching' and 'Patient Recruitment' categories reflects its dual impact on streamlining clinical trial processes and enhancing patient access to cutting-edge therapies. 'Being recognized by CB Insights in two critical categories is a testament to our team's dedication to transforming oncology care,' said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. 'Our AI-driven platform is designed to bridge the gap between patients and clinical trials, ensuring that individuals receive the most appropriate and timely treatments available.' Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer, added, 'This acknowledgment validates our commitment to integrating advanced AI technologies into clinical workflows. By optimizing trial matching and patient recruitment, we're not only improving operational efficiencies but also enhancing patient outcomes in oncology.' This recognition from CB Insights follows a milestone presence at ASCO25, where Arturo Loaiza-Bonilla presented a poster session on AI-powered clinical trial matching and participated in the ASCO/ESMO Joint Session, emphasizing international collaboration in oncology innovation. In addition, Selin Kurnaz was named a PCC Wayfinder, honoring her leadership in advancing equitable access and data-driven transformation in cancer care. Massive Bio's platform utilizes sophisticated algorithms and real-time data analytics to match cancer patients with suitable clinical trials, considering factors such as genetic profiles, treatment histories, and geographic locations. This approach has significantly increased trial enrollment rates and reduced the time required to identify eligible participants. The company's dual recognition by CB Insights highlights its comprehensive approach to addressing challenges in clinical trial enrollment and patient engagement. As the demand for personalized cancer treatments grows, Massive Bio continues to lead in providing scalable, AI-driven solutions that connect patients with life-saving clinical trials. About Massive Bio Massive Bio, co-founded by , Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit

PVEK: New Standard of Care in Rare, Deadly Blood Cancer?
PVEK: New Standard of Care in Rare, Deadly Blood Cancer?

Medscape

time19 hours ago

  • Medscape

PVEK: New Standard of Care in Rare, Deadly Blood Cancer?

CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with good durability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the phase 1/2 CADENZA trial. 'We conclude that PVEK represents a potentially practice-changing paradigm for patients with the rare disease BPDCN,' said study author Naveen Pemmaraju, MD, of MD Anderson Cancer Center in Houston, Texas, during an oral abstract session at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. 'One half of first-line patients treated with PVEK subsequently received stem cell transplant. PVEK treatment had a manageable safety profile, and infusion-related reactions and peripheral edema were resolved with supportive care. No capillary-leak syndrome was observed.' CADENZA enrolled 84 adult patients with CD123-positive BPDCN. Of these patients, 33 were newly diagnosed, and 51 patients had relapsed or refractory (R/R) BPDCN with one, two, or three prior lines of therapy. In the first-line group, 22 patients had de novo disease and 11 had a prior or concomitant hematologic malignancy (PCHM). CADENZA's primary endpoint was the composite rate of complete response (CR) plus CR with minimal skin abnormality (CRc) in the first-line de novo patients. The authors found that 70% of patients achieved the composite CR, while 14% of the patients with R/R disease did. Regarding the overall response rate (ORR), 85% of first-line patients responded to PVEK, while 35% of patients with R/R disease responded. Responses among patients with R/R disease were early and durable (median, 1.4 months and 9.2 months, respectively). PCHM status did not affect overall survival (OS) in first-line patients: Median OS was 16.6 months in both the de novo and PCHM subgroups. The discussant for this study, Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, told Medscape Medical News that the CADENZA trial supports the use of CD123 as a therapeutic target in BPDCN. He also noted that the current standard of care often causes potentially life-threatening capillary leak syndrome (CLS): 'There were no cases of CLS in this dataset, which means we may have an opportunity to deliver anti-CD123 therapies, with no CLS as a potential side effect.' Rampal also cited PVEK's apparent ability to enable many patients to bridge to stem cell transplant, 'the fundamental prospect in terms of long-term survival provisions with BPDCN.' Following this presentation, Pemmaraju sat down with Medscape Medical News . The following interview has been edited for clarity. Please give us some context on BPDCN and why it is difficult to treat. BPDCN is a rare, aggressive hematologic malignancy primarily involving skin, bone marrow, lymph nodes and the central nervous system. We think there are only 500 BPDCN diagnoses per year in the United States. Current treatment regimens are limited to chemotherapy regimens adapted from AML, ALL, lymphoma, and myeloma. The median age at diagnosis is around 65 years, so many patients are not eligible for intensive chemo or stem cell transplant. CD123 is overexpressed on all BPDCN blasts, making it an ideal target for immunochemotherapy. What is the top takeaway from your presentation? BPDCN has an overall poor prognosis with significant unmet need. Currently, tagraxofusp-erzs is the standard of care and the only approved treatment for BPDCN. PVEK is a new CD123-targeting agent. This novel monotherapy, given once every 3 weeks, had high response rates for frontline patients with BPDCN and was highly durable. Even for patients with R/R disease, whose prognosis is only a few months, PVEK showed some promising activity both in response and durability. Patients with BPDCN are in need of improved frontline therapies to treat their disease, so we're very excited to see this phase 1/2 trial going extremely well in terms of safety and efficacy. The responses we have observed make PVEK a strong candidate as a standard-of-care treatment. What is another important thing you want your colleagues to know about this study? The CADENZA trial enrolled 84 patients, which is a huge number in a rare disease field like ours. I'm proud we were able to achieve a real-world demographic split. That means we had older patients, just like I see in the clinic, and half the patients had skin involvement along with bone marrow. In the relapsed group, the prior therapy had been quite intense. Half of these patients had received chemo, half had received tagraxofusp, and a third had received a transplant. This may be the best study I've ever done in terms of enrolling patients who are truly representative with all the comorbidities, and all the difficulties, you see in clinical practice. You mentioned that PVEK is more patient-friendly than the standard of care. Why is that? PVEK is given once every 3 weeks via an infusion that takes only 30 minutes or less. Many of our other drugs, of course, require a much more intensive schedule that can be difficult for patients, especially when they must be given on an inpatient basis. PVEK can be given outpatient even from the beginning, which is much more convenient for patients. You referred several times to patients' skin lesions. Is that part of the BPDCN disease process or is that a treatment reaction? I want to emphasize this is a BPDCN trait not related to treatment. BPDCN has a predilection for the skin. The vast majority of patients with BPDCN, anywhere from 70% to 90%, will present with skin findings. It's very common for my patients to present with 'just' a skin lesion that turns out to be anything but. Unlike other skin-containing malignancies, BPDCN is a bone marrow blood cancer that can go to an acute leukemia and become acutely life threatening. Let's differentiate that from the cutaneous toxicity very commonly seen in chemo-based regimens. What's ahead in PVEK research? We will keep presenting our data, including at the European Hematological Association and as an ASCO Encore presentation. We hope to submit PVEK to regulatory agencies in the near future. Ultimately, can we combine PVEK with other agents active in the AML and BPDCN space to create a next-generation therapy? Eventually, once we have two active agents for BPDCN, we will need to determine the sequencing of these drugs. What's the natural history of these treated patients? Are they living longer? I think answers to all those questions will come out in the coming year or two. The study was funded by AbbVie. Pemmaraju disclosed having relationships with AbbVie, Aplastic Anemia and MDS International Foundation, Aptitude Health, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, CancerNet, CareDx, Celgene, Cimeio Therapeutics, ClearView Healthcare Partners, CTI BioPharma Corp, Curio Science, Dava Oncology, EUSA Pharma, Harborside Press, Imedex, ImmunoGen, Intellisphere, Magdalen Medical Publishing, Medscape, Menarini Group, Neopharm, Novartis, OncLive, Pacylex, Patient Power, Peerview, PharmaEssentia, and Physicians' Education Resource. Rampal reported having ties with AbbVie, Blueprint Medicines, Bristol Myers Squibb/Celgene, Constellation Pharmaceuticals, CTI BioPharma Corp, Disc Medicine, Galecto, Incyte, Karyopharm Therapeutics, Novartis, Pharmaessentia, Promedior, SERVIER, Sierra Oncology, Stemline Therapeutics, Sumitomo Dainippon, and Zentalis.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store